Initial Observations of Cell-Mediated Drug Delivery to the Deep Lung

Author(s)Glaum, M.
Author(s)Kumar, Arun (Professor)
Author(s)El-Badri, N.
Author(s)Mohapatra, S.
Author(s)Haller, E.
Author(s)Park, Sunhee
Author(s)Patrick, L.
Author(s)Nattkemper, L.
Author(s)Vo, D.
Author(s)Cameron, D. F.
Ordered AuthorKumar, A., Glaum, M., El-Badri, N., Mohapatra, S., Haller, E., Park, S., Patrick, L., Nattkemper, L., Vo, D., Cameron, D. F.
UD AuthorKumar, Arun (Professor)
Date Accessioned2014-07-25T19:17:43Z
Date Available2014-07-25T19:17:43Z
Copyright DateCopyright © 2011 Cognizant Comm. Corp.
Publication Date2011
DescriptionFinal published version
AbstractUsing current methodologies, drug delivery to small airways, terminal bronchioles, and alveoli (deep lung) is inefficient, especially to the lower lungs. Urgent lung pathologies such as acute respiratory distress syndrome (ARDS) and post-lung transplantation complications are difficult to treat, in part due to the methodological limitations in targeting the deep lung with high efficiency drug distribution to the site of pathology. To overcome drug delivery limitations inhibiting the optimization of deep lung therapy, isolated rat Sertoli cells preloaded with chitosan nanoparticles were use to obtain a high-density distribution and concentration (92%) of the nanoparticles in the lungs of mice by way of the peripheral venous vasculature rather than the more commonly used pulmonary route. Additionally, Sertoli cells were preloaded with chitosan nanoparticles coupled with the anti-inflammatory compound curcumin and then injected intravenously into control or experimental mice with deep lung inflammation. By 24 h postinjection, most of the curcumin load ( 90%) delivered in the injected Sertoli cells was present and distributed throughout the lungs, including the perialveloar sac area in the lower lungs. This was based on the high-density, positive quantification of both nanoparticles and curcumin in the lungs. There was a marked positive therapeutic effect achieved 24 h following curcumin treatment delivered by this Sertoli cell nanoparticle protocol (SNAP). Results identify a novel and efficient protocol for targeted delivery of drugs to the deep lung mediated by extratesticular Sertoli cells. Utilization of SNAP delivery may optimize drug therapy for conditions such as ARDS, status asthmaticus, pulmonary hypertension, lung cancer, and complications following lung transplantation where the use of high concentrations of anti-inflammatory drugs is desirable, but often limited by risks of systemic drug toxicity.en_US
DepartmentUniversity of Delaware. Department of Medical Laboratory Sciences.
CitationKumar, A., Glam, M., El-Badri, N., Mohapatra, S., Haller, E., Park, S., . . . Cameron, D. F. (2011). Initial observations of cell-mediated drug delivery to the deep lung. Cell Transplantation, 20(5), 609-618. doi:10.3727/096368910X536491
dc.languageEnglish (United States)
PublisherCognizant Communication Corporationen_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
dc.sourceCell Transplantation
KeywordsDrug deliveryen_US
KeywordsDeep lungen_US
KeywordsSertoli cellsen_US
TitleInitial Observations of Cell-Mediated Drug Delivery to the Deep Lungen_US
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
7.6 MB
Adobe Portable Document Format
Downloadable Full Text
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
2.22 KB
Item-specific license agreed upon to submission